Yerim An1, Sung Pyo Park1, Yong-Kyu Kim2. 1. Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, #150 Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea. 2. Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, #150 Seongan-ro, Gangdong-gu, Seoul, 05355, South Korea. ykkim3@gmail.com.
Abstract
PURPOSE: We aimed to investigate the association between subfoveal choroidal thickness (SCT) and the level of aqueous humor (AH) inflammatory cytokines in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO). METHODS: Twenty-eight eyes of 28 BRVO ME patients who underwent intravitreal injection treatment (ranibizumab, bevacizumab, or dexamethasone implant) were prospectively recruited. The concentrations of vascular endothelial growth factor (VEGF)-A and inflammatory cytokines were measured from AH samples. We analyzed clinical factors associated with visual gain or the degree of central macular thickness (CMT) decrease and the association between SCT and inflammatory cytokine levels. RESULTS: On multiple linear regression analysis, the AH interleukin (IL)-8 level was significantly associated with visual gain and CMT reduction at 6 months. Age, systemic hypertension, and AH monocyte chemo-attractant protein 1 level showed a significant association with baseline SCT, and VEGF-A showed a significant association with baseline SCT ratio (BRVO eye SCT/fellow eye SCT). Those with thick SCT showed a higher level of AH soluble VEGF receptors 2 and IL-8 and showed better visual gain and greater CMT reduction at 2 and 6 months compared to the thin SCT group. CONCLUSIONS: The level of AH inflammatory cytokines was significantly associated with the ischemic status of the retina, treatment outcomes, and SCT in BRVO ME patients. Thick baseline SCT might be a predictive sign for better treatment outcomes in BRVO ME patients which are thought to be related to a higher level of intraocular inflammatory cytokines in these patients.
PURPOSE: We aimed to investigate the association between subfoveal choroidal thickness (SCT) and the level of aqueous humor (AH) inflammatory cytokines in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO). METHODS: Twenty-eight eyes of 28 BRVO ME patients who underwent intravitreal injection treatment (ranibizumab, bevacizumab, or dexamethasone implant) were prospectively recruited. The concentrations of vascular endothelial growth factor (VEGF)-A and inflammatory cytokines were measured from AH samples. We analyzed clinical factors associated with visual gain or the degree of central macular thickness (CMT) decrease and the association between SCT and inflammatory cytokine levels. RESULTS: On multiple linear regression analysis, the AH interleukin (IL)-8 level was significantly associated with visual gain and CMT reduction at 6 months. Age, systemic hypertension, and AH monocyte chemo-attractant protein 1 level showed a significant association with baseline SCT, and VEGF-A showed a significant association with baseline SCT ratio (BRVO eye SCT/fellow eye SCT). Those with thick SCT showed a higher level of AH soluble VEGF receptors 2 and IL-8 and showed better visual gain and greater CMT reduction at 2 and 6 months compared to the thin SCT group. CONCLUSIONS: The level of AH inflammatory cytokines was significantly associated with the ischemic status of the retina, treatment outcomes, and SCT in BRVO ME patients. Thick baseline SCT might be a predictive sign for better treatment outcomes in BRVO ME patients which are thought to be related to a higher level of intraocular inflammatory cytokines in these patients.
Authors: H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima Journal: Eye (Lond) Date: 2006-07-07 Impact factor: 3.775
Authors: Tien Yin Wong; Emily K Marino Larsen; Ronald Klein; Paul Mitchell; David J Couper; Barbara E K Klein; Larry D Hubbard; David S Siscovick; A Richey Sharrett Journal: Ophthalmology Date: 2005-04 Impact factor: 12.079
Authors: Ning Cheung; Ronald Klein; Jie Jin Wang; Mary Frances Cotch; Amirul F M Islam; Barbara E K Klein; Mary Cushman; Tien Yin Wong Journal: Invest Ophthalmol Vis Sci Date: 2008-06-06 Impact factor: 4.799
Authors: Marion Funk; Katharina Kriechbaum; Franz Prager; Thomas Benesch; Michael Georgopoulos; Gerhard J Zlabinger; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2008-12-05 Impact factor: 4.799